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Supplementary Figure S1. MHG-8 and LHG-10 inhibit production of active TGF-β1 by human polyclonal Tregs. 
After a short in vitro amplification, human CD4+CD25hiCD127lo cells (Tregs) were re-stimulated with anti-CD3/CD28 coated 
beads during 24 hours, in the presence or absence of the indicated mAbs (10 µg/ml). Plato-1, 272G6, 50G10 and 7B11 are 
commercially available anti-hGARP mAbs. Cells lysates were analyzed by Western Blot with antibodies against phosphorylated 
SMAD2 (pSMAD2) as a read-out for active TGF-β1 production, or β-ACTIN as loading control. Bar graphs show quantifica- 
tion of ECL signals, represented as ratios of pSMAD2 to β-ACTIN, normalized to the ratio in cells stimulated in the absence of 













































































































































Supplementary Figure S2. Some anti-hGARP mAbs bind free GARP only. 
Cell lysates of BW5147 cells transfected with hGARP and hTGFB1 were immunoprecipitated with the indicated anti-hGARP 
mAbs. Total lysates (BW5147+hGARP+hTGFB1 or untransfected controls; 30% of input in IP) and IP products were analysed by 
Western Blot with antibodies against hGARP (clone Plato-1), LAP or the mature TGF-β1 peptide. IPs with mAbs representative 
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Supplementary Figure S3. Detailed results of experiments I, II, and III summarized in Fig. 5B. 
Graphs show progression of disease score (mean + sem) and survival. Numbers of mice per group are indicated in Fig. 5B. 
Statistical significance of differences were calculated using 2-way ANOVA followed by a Bonferroni post hoc test for disease 
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Supplementary Figure S4. Analyses of tissues from NSG mice grafted with human PBMCs. 
Sections from lung and liver of NSG mice grafted with human PBMCs +/- Tregs, and treated or not with MHG-8, anti-TGF-β or 
isotype control antibodies as indicated in Fig. 5A, were stained with Hematoxilin/Eosin (HE) or with antibodies against human CD4 
(hCD4) or CD8 (hCD8).  Organs were collected from mice with a GVHD score of 6 at the indicated day post graft. Arrows in liver 
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Supplementary Figure S5. FACS analysis of splenocytes collected from NSG mice at various time points after transfer of 
human PBMCs ± Tregs. 
NSG mice injected as in Fig. 5A with human cells and antibodies indicated on the right were sacrificed at various time points 
after cell transfer. Permeabilized splenocytes were labeled with a Live/Dead cell marker, anti-hCD45, anti-hCD4, anti-hFOXP3 
and MHG-6 antibodies (plots on the left), or with a Live/Dead cell marker, anti-hCD4, anti-hCD45RA, and anti-hFOXP3 (plots 
on the right). One representative mouse per group is represented (n = 2 mice per group). The gating strategy is indicated on top 
of the density plots. Dotted horizontal lines indicate the delineation between FOXP3lo and FOXP3hi cells. In the density plots on 
the left, the rectangle and the percentage below indicate GARP+ cells in CD4+FOXP3+ cells. In the density plots on the right, 
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Supplementary Figure S6. Human fibroblasts express GARP but do not produce active TGF-β1. 
Human primary fibroblast cell lines were derived from abdominal plasty or tumor fragments. Cells were plated in complete 
medium. After 24 hrs, medium was changed to X-VIVO10, and cells were incubated for an additional 24 hours. In conditions 
indicated on the figure, MHG-8 was added at a final concentration of 10 µg/ml during the last 24 hours of culture, or recombi- 
nant hTGF-β1 was added during the last 30 minutes of culture. Cell lysates were analyzed by Western blot with anti-GARP, 
























































































































































0    50K 
 
100K 150K 200K 250K 
FSC-A 
 


















































10 2 102 
0 0 






0     50K  100K 150K 200K 250K 0 102 103       104 105 0  102 103       104 105 







GATE = 1 
 
 
GATE = 2 
 
 















Used to measure cells: 
































































FSC-A hCD3-APC hFoxP3-PeYG Isotype-PeYG 
Negative control 






NO GATE  
105 








Used to measure cells: 
 
105 





























































































































GATE = 1 
105   15%  4% 
2 







Used to measure cells: 
no prim. + SAPE 
Negative control 










8%  9% 
2 hCD4+hFOXP3hihCD45RA- 
 
10 2 10 
2
 










Supplementary Figure S7. Gating strategies, isotype controls, and representative stains for all flow experiments. 
































































































































Supplementary Figure S8. Source data for figures showing Western 
blot analyses. 15 
Uncropped Western blot images used in the figures. Some membranes 10 
were cut along horizontal lines in two or three parts before hybridization. 
Donor 
Supplementary Table S1. Purity of polyclonal human Tregs. 
 
 








cells by MS-qPCR Used in 
 
 
on day of sorting on day of sorting  after 12 to 14 
days of culture 
 
A 95% 101% 93% Fig. 5B 
B (sort #1) 93%  97% 81% Fig. 5B 
B (sort #2)                        99%                                80%                         64%                 Fig. 6A-C  
C                               91%                                73%                         55%                  Fig. 5B,C 
D                               92%                                93%                         70%                  Fig. 5B,D 
E                               84%                                92%                         97%                  Supp. Fig. S1 
F                        not determined                            84%                         69%                  Fig. 6D; Supp. Fig. S5 
